Tome Biosciences

A USA-based programmable genomic integration (PGI) company

Tome launched in December 2023, having raised $213 million in Series A and B funding from investors. A month later, it acquired Replace Therapeutics, a private biotech company developing a novel PGI method capable of inserting and deleting small DNA sequences.